A5020890006- Virus-based gene therapy research
- Viral Infections and Immunology Research
- RNA Interference and Gene Delivery
- Pulmonary Hypertension Research and Treatments
- Cardiac Valve Diseases and Treatments
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- CRISPR and Genetic Engineering
- Aortic Disease and Treatment Approaches
- Cardiovascular Function and Risk Factors
- Congenital Heart Disease Studies
- Cardiac Fibrosis and Remodeling
- Cardiac electrophysiology and arrhythmias
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrhythmias and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Cardiac, Anesthesia and Surgical Outcomes
- CAR-T cell therapy research
- Cardiac pacing and defibrillation studies
- Cardiac tumors and thrombi
- Signaling Pathways in Disease
- Electrospun Nanofibers in Biomedical Applications
- Circular RNAs in diseases
- Cardiomyopathy and Myosin Studies
- Cardiac Ischemia and Reperfusion
Icahn School of Medicine at Mount Sinai
2016-2025
Cardiovascular Institute of the South
2019-2020
Morristown Medical Center
2020
Cedars-Sinai Smidt Heart Institute
2020
Alaska Heart and Vascular Institute
2020
Cardiovascular Research Center
2018-2019
Abington Memorial Hospital
2018
Mount Sinai Hospital
2018
University of Rochester
2017
Bon Secours Heart & Vascular Institute
2016
Sphingolipids have recently emerged as a biomarker of recurrence and mortality after myocardial infarction (MI). The increased ceramide levels in mammalian heart tissues during acute MI, demonstrated by several groups, is associated with higher cell death rates the left ventricle deteriorated cardiac function. Ceramidase, only enzyme known to hydrolyze proapoptotic ceramide, generates sphingosine, which then phosphorylated sphingosine kinase produce prosurvival molecule...
Gene therapy with adeno-associated virus (AAV)-based vectors shows great promise for the gene therapeutic treatment of a broad array diseases. In fact, genetic diseases AAV is currently only in vivo approach that approved by US Food and Drug Administration (FDA). Unfortunately, pre-existing antibodies against severely limit patient population can potentially benefit from therapy, especially if vector delivered intravenous injection. Here, we demonstrate selectively deplete anti-AAV...
Inhibition of pulmonary fibrosis (PF) by restoring sarco/endoplasmic reticulum calcium ATPase 2a isoform (SERCA2a) expression using targeted gene therapy may be a potentially powerful new treatment approach for PF. Here, we found that SERCA2a was significantly decreased in lung samples from patients with PF and the bleomycin (BLM) mouse model In BLM-induced model, intratracheal aerosolized adeno-associated virus serotype 1 (AAV1) encoding human (AAV1.hSERCA2a) reduces associated vascular...